组蛋白甲基化及乙酰化修饰酶在卵巢癌中的机制研究及治疗进展

Mechanisms of histone methylation and acetylation modifying enzymes in ovarian cancer and therapeutic advances

卵巢癌是恶性程度最高的妇科恶性肿瘤。近年来,组蛋白修饰(histone modifying enzymes,HMEs)作为表观遗传修饰的重要部分在卵巢癌中被广泛研究,包括组蛋白甲基转移酶及去甲基酶、组蛋白乙酰转移酶及去乙酰化酶在内的多种组蛋白修饰酶通过对组蛋白及非组蛋白进行修饰,在卵巢癌细胞的增殖、迁移等方面发挥了重要作用,并且能够调控化疗耐药的发生。多种组蛋白修饰酶的抑制剂通过促进细胞生长停滞及凋亡、抑制肿瘤细胞的侵袭、增加化疗敏感性等在卵巢癌中发挥良好的抗肿瘤作用,有望成为卵巢癌精准治疗的新策略。本文将针对参与甲基化及乙酰化过程的组蛋白修饰酶在卵巢癌中的作用机制及治疗潜力作一综述。

Ovarian cancer is the most malignant gynecologic malignancy.In recent years,histone modifying enzymes(HMEs)have been widely studied as an important part of epigenetic modifications in ovarian cancer.Histone modifying enzymes,including histone methyltransferases and demethylases,histone acetyltransferases and deacetylases,play an important role in the proliferation and migration of ovarian cancer cells by modifying histone and non-histone proteins,and can regulate the development of chemoresistance.Inhibitors of various histone modifying enzymes play good anti-tumor effects in ovarian cancer by promoting cell growth arrest and apoptosis,inhibiting tumor cell invasion,and increasing chemotherapy sensitivity,and are expected to be a new strategy for precision treatment of ovarian cancer.Therefore,this paper will review the mechanism of action and therapeutic potential of histone modifying enzymes involved in methylation and acetylation processes in ovarian cancer.